Bulk biological nucleophiles

Bulk biological nucleophiles refer to the diverse array of electron-rich chemical groups found within cellular macromolecules and metabolites, including the thiol groups of glutathione and cysteine, the amino groups of lysine and nucleic acids, and the phosphate groups of the DNA backbone (DrugBank). In clinical pharmacology, this target is primarily associated with the action of alkylating agents and other highly reactive electrophilic drugs used in the treatment of various cancers and autoimmune disorders (PubMed, PMID: 25135306). These drugs exert their effects by forming covalent bonds with nucleophilic sites, most critically the N7 position of guanine in DNA, which leads to DNA cross-linking, strand breakage, and the induction of apoptosis. However, because these reactions are inherently non-specific, the drugs also bind to a wide array of non-target proteins and small molecules, which is a major driver of systemic toxicities such as myelosuppression and hepatotoxicity (StatPearls, NBK545230). Consequently, the availability and reactivity of bulk biological nucleophiles within a tissue significantly influence the therapeutic efficacy and the safety profile of electrophilic medicinal agents.

Other names

Biological nucleophilesCellular nucleophilesEndogenous nucleophilesNucleophilic sites

Drugs targeting bulk biological nucleophiles act as electrophiles that form covalent bonds with electron-rich groups on DNA, proteins, and small molecules (DrugBank). The primary therapeutic mechanism involves the alkylation of DNA, particularly at the N7 position of guanine, which causes DNA cross-linking and strand breaks, thereby inhibiting replication and inducing apoptosis (PubMed, PMID: 25135306). These drugs also react with non-target nucleophiles like glutathione and various proteins, contributing to their overall pharmacological and toxicological profile (StatPearls, NBK545230).